Scrip
US buys 30,000 courses of intravenous antivirals for H1N1 - updated
09 November 2009
Sue Sutter
Please Login to read the full article.
09 November 2009
Sue Sutter
sue.sutter@informa.com
BioCryst Pharmaceuticals has shipped 10,000 treatment courses of its intravenous antiviral peramivir to the US
health and human services (HHS) department under a $22.5 million contract aimed at countering the toll of H1N1 influenza. The order came less than two weeks after the FDA authorised peramivir,...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US moves closer to allowing emergency use of peramivir for H1N1
- BioCryst signs two more non-US partnerships for peramivir
- US FDA reinforces mandatory adverse event reporting for BioCryst's IV peramivir
- US FDA authorises BioCryst's IV peramivir for emergency H1N1 use – updated
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
